Quick Ratios
Quarterly Results
Profit & Loss
Balance Sheet
Cash Flow
Ratios
Mkt Cap
Market Capitalization
₹21,783Cr
Rev Gr TTM
Revenue Growth TTM
2.89%
Peer Comparison
Compare up to 10 companies side by side across valuation, profitability, and growth.

SUMICHEM
VS
| Quarter | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|
|
Growth YoY Revenue Growth YoY% | -2.0 | -26.5 | -19.4 | -28.0 | 3.5 | 15.8 | 9.4 | 18.4 | 0.8 | 26.0 | -5.9 | -11.5 |
| 571 | 644 | 716 | 476 | 534 | 678 | 743 | 536 | 560 | 838 | 712 | 468 |
Operating Profit Operating ProfitCr |
| 12.4 | 11.1 | 20.8 | 12.1 | 20.8 | 19.2 | 24.8 | 16.5 | 17.6 | 20.7 | 23.4 | 17.5 |
Other Income Other IncomeCr | 16 | 18 | 25 | 27 | 27 | 26 | 31 | 31 | 32 | 39 | 39 | 21 |
Interest Expense Interest ExpenseCr | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 |
Depreciation DepreciationCr | 14 | 14 | 16 | 16 | 17 | 15 | 16 | 19 | 16 | 16 | 17 | 17 |
| 82 | 83 | 195 | 75 | 149 | 171 | 260 | 117 | 133 | 241 | 238 | 102 |
| 10 | 22 | 52 | 21 | 39 | 44 | 67 | 29 | 33 | 63 | 60 | 26 |
|
Growth YoY PAT Growth YoY% | -3.4 | -55.4 | -28.8 | -39.5 | 52.4 | 105.4 | 34.2 | 59.8 | -9.2 | 40.6 | -7.7 | -13.3 |
| 11.1 | 8.5 | 15.9 | 10.1 | 16.3 | 15.1 | 19.5 | 13.6 | 14.7 | 16.9 | 19.1 | 13.3 |
| 1.4 | 1.2 | 2.9 | 1.1 | 2.2 | 2.5 | 3.9 | 1.7 | 2.0 | 3.6 | 3.6 | 1.5 |
| Financial Year | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|
|
| | 15.6 | 9.6 | 9.1 | 15.7 | 14.7 | -19.0 | 10.7 | 2.7 |
| 1,696 | 1,948 | 2,092 | 2,158 | 2,461 | 2,844 | 2,369 | 2,516 | 2,578 |
Operating Profit Operating ProfitCr |
| 11.3 | 11.9 | 13.7 | 18.4 | 19.6 | 19.0 | 16.7 | 20.1 | 20.3 |
Other Income Other IncomeCr | 30 | 28 | -20 | 19 | 27 | 45 | 96 | 120 | 130 |
Interest Expense Interest ExpenseCr | 3 | 4 | 6 | 6 | 6 | 5 | 5 | 6 | 8 |
Depreciation DepreciationCr | 24 | 28 | 41 | 47 | 45 | 52 | 62 | 66 | 66 |
| 221 | 260 | 267 | 453 | 576 | 654 | 503 | 680 | 713 |
| 76 | 94 | 62 | 108 | 152 | 152 | 133 | 174 | 182 |
|
| | 14.3 | 23.5 | 68.7 | 22.6 | 18.6 | -26.4 | 37.0 | 4.9 |
| 7.6 | 7.5 | 8.4 | 13.1 | 13.8 | 14.3 | 13.0 | 16.1 | 16.4 |
| 2.9 | 3.3 | 4.1 | 6.9 | 8.5 | 10.1 | 7.4 | 10.1 | 10.7 |
| Financial Year | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|
Equity Capital Equity CapitalCr | 275 | 275 | 499 | 499 | 499 | 499 | 499 | 499 | 499 |
| 679 | 774 | 723 | 1,042 | 1,428 | 1,883 | 1,942 | 2,402 | 2,698 |
Current Liabilities Current LiabilitiesCr | 672 | 776 | 840 | 1,081 | 1,021 | 933 | 801 | 965 | 1,136 |
Non Current Liabilities Non Current LiabilitiesCr | 33 | 35 | 45 | 50 | 61 | 54 | 68 | 94 | 102 |
Total Liabilities Total LiabilitiesCr |
Current Assets Current AssetsCr | 1,346 | 1,541 | 1,746 | 2,304 | 2,522 | 2,788 | 2,673 | 3,020 | 3,545 |
Non Current Assets Non Current AssetsCr | 313 | 319 | 361 | 368 | 488 | 581 | 640 | 944 | 894 |
Total Assets Total AssetsCr |
| Financial Year | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|
Operating Cash Flow Operating Cash FlowCr | 47 | 78 | 221 | 425 | 222 | 389 | 757 | 453 |
Investing Cash Flow Investing Cash FlowCr | -40 | -35 | -118 | -283 | -290 | -327 | -420 | -392 |
Financing Cash Flow Financing Cash FlowCr | 7 | -65 | -61 | -47 | -63 | -73 | -337 | -69 |
|
Free Cash Flow Free Cash FlowCr | 4 | 39 | 184 | 383 | 109 | 270 | 695 | 424 |
| 32.7 | 46.9 | 108.2 | 123.2 | 52.4 | 77.5 | 204.8 | 89.4 |
CFO To EBITDA CFO To EBITDA% | 21.9 | 29.5 | 66.5 | 87.4 | 37.0 | 58.4 | 159.6 | 71.6 |
| Financial Year | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|
Valuation Ratios Valuation Ratios |
Market Cap Market CapitalizationCr | 0 | 0 | 9,157 | 14,515 | 22,439 | 21,226 | 17,340 | 27,890 |
Price To Earnings Price To Earnings | 0.0 | 0.0 | 44.7 | 42.0 | 53.0 | 42.3 | 47.0 | 55.2 |
Price To Sales Price To Sales | 0.0 | 0.0 | 3.8 | 5.5 | 7.3 | 6.0 | 6.1 | 8.9 |
Price To Book Price To Book | 0.0 | 0.0 | 7.5 | 9.4 | 11.6 | 8.9 | 7.1 | 9.6 |
| -0.3 | -0.1 | 27.3 | 29.4 | 37.3 | 31.4 | 36.2 | 44.1 |
Profitability Ratios Profitability Ratios |
| 35.2 | 34.0 | 33.7 | 37.4 | 37.7 | 35.3 | 37.6 | 41.0 |
| 11.3 | 11.9 | 13.7 | 18.4 | 19.6 | 19.0 | 16.7 | 20.1 |
| 7.6 | 7.5 | 8.4 | 13.1 | 13.8 | 14.3 | 13.0 | 16.1 |
| 23.2 | 24.7 | 21.6 | 29.2 | 29.6 | 27.3 | 20.6 | 23.2 |
| 15.2 | 15.8 | 16.8 | 22.4 | 22.0 | 21.1 | 15.1 | 17.5 |
| 8.8 | 8.9 | 9.7 | 12.9 | 14.1 | 14.9 | 11.2 | 12.8 |
Operational Ratios Operational Ratios |
Solvency Ratios Solvency Ratios |
Liquidity Ratios Liquidity Ratios |
### **Overview**
Sumitomo Chemical India Ltd. (SCIL) is a leading Indian agrochemical company and the flagship entity of the global Sumitomo Chemical Company (SCC) Group, Japan. With over two decades of operations in India, SCIL has established itself as a key player in the crop protection, environmental health, and animal nutrition sectors. Backed by strong R&D capabilities, backward integration, a robust distribution network, and digital innovation, SCIL combines global scale with localized market execution to deliver sustainable, eco-friendly solutions to Indian and international farmers.
---
### **Core Strengths & Strategic Positioning**
#### **1. Market Leadership and Diversified Portfolio**
- SCIL holds a dominant position in the Indian agrochemical market, with leadership across both product categories and manufacturing processes.
- The company offers a balanced and diversified portfolio spanning **insecticides, herbicides (weedicides), fungicides, fumigants, rodenticides, plant growth regulators (PGRs), bio-rationals, and nutrients**, serving over **200 brands and 700+ SKUs**.
- It is one of the few Indian companies offering both **chemical and biological crop protection products**, giving it a competitive edge in the shift toward sustainable agriculture.
- No single product or molecule contributes more than **~15% of revenue**, and the top 10 products account for **less than 45% of total revenue**, reducing dependency and enhancing resilience.
- The portfolio is strategically aligned with high-growth, high-margin segments: **herbicides, PGRs, and bio-rational products**, with deliberate efforts to expand PGR offerings for both **Kharif and Rabi seasons** to reduce seasonality.
#### **2. Manufacturing & Backward Integration**
- SCIL operates **five state-of-the-art manufacturing facilities** across Gujarat, Maharashtra, and Silvassa – at **Bhavnagar (~58 acres), Gajod (~120 acres), Tarapur (~5 acres), Vapi (~6 acres), and Silvassa (~3 acres)** – totaling **~190 acres** of production land.
- These strategically located plants specialize in **technical-grade pesticides (TGAI), formulations, metal phosphides, and water-dispersible granules (WDG)**, with 80–90% capacity utilization.
- Key products include **glyphosate, chlorpyrifos, imidacloprid, tebuconazole, aluminum phosphide,** and **sulfur WDG**.
- The company has significant **backward integration capabilities**, particularly in active ingredient manufacturing, reducing import dependence and improving cost control.
#### **3. Global R&D Powerhouse & Innovation**
- SCIL leverages the **global R&D and supply chain capabilities** of its parent, SCC Japan, while maintaining strong in-house innovation in India.
- It operates **three DSIR-approved R&D laboratories** in **Mumbai, Bhavnagar, and Gajod**, staffed by **over 75 scientists and engineers**, including **30+ PhDs**.
- Focus areas include **off-patent products, novel formulations, combination products, reduced toxicity solutions**, and **green chemistry**.
- The company has filed **over 25 patents globally**, with five patent applications in progress, and holds more than **200 product registrations**.
- SCIL is actively developing **proprietary molecules from SCC Japan** for local manufacturing under the **"Make in India" initiative**, positioning itself as a global manufacturing hub.
---
### **Growth Drivers & Expansion Strategy**
#### **1. Greenfield & Brownfield Expansions (Dahej & Tarapur)**
- A **50-acre freehold land parcel** has been acquired at **Dahej PCPIR** for a **large-scale Greenfield manufacturing project**, with environmental clearance secured.
- The Dahej project will house multiple plants for **SCC-innovated proprietary molecules and intermediates**, supported by a **10-year environmental license**.
- A **second plant for a key SCC-innovated product** is being established at **Bhavnagar**, and a **brownfield expansion at Tarapur** will produce a new global blockbuster molecule.
- The Tarapur Brownfield project (CAPEX < ₹10 crore) aims to meet **100% of domestic demand** within two years and serve as a bridge until Dahej plants are operational.
#### **2. Capital Investment & CAPEX Outlook**
- **Regular CAPEX**: ₹70–75 crore/year for maintenance, efficiency, and upgrades.
- **Strategic CAPEX**:
- ₹120–300 crore invested in proprietary molecule production projects.
- ₹55 crore approved to double capacity of an existing high-utilization plant for export.
- Focus on **backward integration, capacity expansion, digital infrastructure, and sustainability (GX & DX)**.
#### **3. Export Growth & Global Footprint**
- Exports reach **over 50 countries** across **Latin America, Africa, Asia Pacific, Europe, Middle East, and North America**.
- Exports contribute **~30–35% of total revenue**, with growth driven by **off-patent molecules, bulk technical-grade supplies, and proprietary formulations**.
- **Synergies with Sumitomo Chemicals Latin America (SCLA)** enable stronger market penetration.
- The company is evaluating registration of existing brands for **European markets**, with bioproducts showing strong potential.
---
### **Digital & Sustainable Transformation (DX & GX)**
#### **Digital Transformation (DX) – “Phygital” Engagement**
- SCIL has pioneered a **phygital (physical + digital)** model to engage rural India’s **442 million internet users** and **425 million smartphone owners**.
- Key digital initiatives:
- **814 localized, voice-search-optimized landing pages** in regional dialects.
- **639 precision-targeted digital campaigns** aligned with crop cycles and regional needs.
- **14.2 crore digital touchpoints** generated, reducing marketing costs by **17.2%** via programmatic ad delivery.
- 23 websites in 9 languages; over **53,000 YouTube subscribers**; 100s of live sessions on YouTube, Facebook, Zoom.
- **"Every Day Farmer’s Day" (EDFD)** – a grassroots outreach program – has engaged **over 1 million farmers and thousands of channel partners**.
#### **Field Activity Tracking & Digital Field Days**
- Two proprietary apps – **Sumitomo Connect** and **Sumitomo Field Connect** – track field activities in real time.
- **“Phygital” Field Days** combine on-ground demonstrations with **live digital interactions involving agronomists, R&D teams, and farmers**, enhancing trust and feedback loops.
#### **Green Transformation (GX)**
- **Renewable Energy**: **38% of energy needs** met via **solar and wind projects**, with plans to increase this share.
- **Sustainability Leadership**: Offers **one of the highest shares of environmentally friendly products** in the industry.
- Focus on **eco-friendly formulations, bio-rationals, and low-toxicity products** under the Custom Solutions Division.
---
### **Strategic Acquisitions & Collaborations**
#### **Acquisition of Barrix Agro Sciences (Dec 2023)**
- Acquired **85% stake** in Bengaluru-based **Barrix Agro Sciences**, a leader in **Integrated Pest Management (IPM)** and **Integrated Plant Nutrition Management (IPNM)**.
- Barrix specializes in **pheromone traps, chromatic sheets, and green dispersion technologies**.
- In FY25, Barrix achieved **82% revenue growth** and turned **EBITDA profitable at 16%**, validating successful integration.
- This move strengthens SCIL’s leadership in **bio-solutions** and supports SCC Japan’s global **green chemistry strategy**.
#### **Marketing Global Brands in India**
- SCIL is the **exclusive domestic marketer** for:
- Proprietary agrochemicals, animal nutrition, and environmental health products of **Sumitomo Chemical Company, Japan**.
- Products from **Valent Bio-Sciences (US-based affiliate)**, including **bio-stimulants and growth regulators**.
---
### **Financial & Operational Performance**
- Achieved **highest profitability in FY2024–25** in terms of **PAT and EBITDA margins** despite global headwinds.
- Domestic growth driven by **strong crop seasons, digital campaigns, and new product launches**.
- Export growth sustained via **volume gains and expanded registrations**, particularly in **Africa and Latin America**.
- Inventory optimization completed by **Jul 2024**, normalizing margins post high-cost carryover.
---
### **Recent Product Launches & Pipeline**
- **New domestic launches in FY25–26** include:
- **INDIFLIN (marketed as Excalia Max)** – a patented, high-potential molecule from SCC.
- **Lentigo**, a next-gen herbicide for rice.
- **Meshi, Portion, Ormie, Pyclome, Danitol NXT**, and **Sumiblue Diamond**.
- **Registration secured** for two novel herbicides: **Excalia Max** and **Lentigo**.
- Pipeline includes **3–4 new products** under the **9(4) registration framework**, with focus on **high-efficacy, low-toxicity, eco-friendly formulations**.
---
### **Key Milestones in 2024–25**
- **25th Anniversary** of SCIL in India (FY2024–25).
- Commenced commercial sales from **two new manufacturing plants**, focusing on **global proprietary molecules**.
- Successfully launched **multiple phygital campaigns** and scaled up **digital engagement** to **22–23 million farmers**.
- Achieved **debt-free status**, with strong return ratios and robust operational margins.